Discovery and Repurposing of Multi-Target Senolytics through Structure-Based Virtual Screening

Samael Olacoaga,Mina Königsberg,Francisco Cortés-Benítez,Jaime Pérez-Villanueva,Norma Edith López-Diazguerrero
DOI: https://doi.org/10.1101/2024.07.09.602796
2024-07-14
Abstract:Cellular Senescence is a state of irreversible cell cycle arrest in response to various stressors that can damage the cell. Senescent Cells (SCs) exhibit multiple alterations at the morphological and molecular levels, one of the most significant being the development and activation of Senescent Cell Anti-Apoptotic Pathways (SCAPs). Due to this characteristic, SCs accumulate in organs and tissues during aging. The accumulation of these cells has been associated with the onset and progression of various chronic degenerative diseases, and their selective elimination allows for the slowing down, halting, and reversing of many ageassociated ailments. Small molecules called senolytics, which inhibit SCAPs, have been proposed to selectively eliminate SCs. Herein, we identified new senolytics through computational and rational drug design approaches. Among the identified molecules are the FDA-approved drug tolvaptan, the experimental Phase II drug sotrastaurin, and the experimental drugs cryptotanshinone and bicuculline. The effectiveness of these molecules in targeting senescent cells was confirmed through experiments using two different models of cellular senescence in human lung fibroblasts. Our results suggest that some molecules work by selectively inducing apoptosis through a multi-target mechanism, inhibiting several SCAPs, including PIK3CD, SERPINE1, EFNB1, and PDGFB. These newly identified FDAapproved and experimental drugs have the potential to be repurposed as new senolytic agents.
Bioinformatics
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to identify new small - molecule drugs for multi - target selective clearance of senescent cells (Senolytics). Specifically, through a structure - based virtual screening method, researchers searched for compounds that can effectively inhibit multiple senescent cell anti - apoptotic pathways (SCAPs) from known FDA - approved drugs and experimental drugs. These compounds include Tolvaptan, Sotrastaurin, Cryptotanshinone and Bicuculline. The main goal of the study is to slow down, prevent or even reverse the development of age - related chronic degenerative diseases through these newly discovered multi - target selective senescent cell - clearing drugs, thereby improving healthspan and overall lifespan. The research background indicates that cellular senescence is an irreversible cell - cycle arrest state, usually in response to various stressors. Senescent cells exhibit multiple morphological and molecular - level changes, the most significant of which is the development and activation of senescent cell anti - apoptotic pathways. Due to this characteristic, senescent cells accumulate in organs and tissues with age, which is related to the initiation and development of multiple chronic degenerative diseases. Therefore, selectively eliminating these senescent cells has become a potential treatment strategy, and small - molecule selective clearance agents (Senolytics) have been proposed as tools to achieve this goal. The first - generation selective clearance agents mentioned in the paper, such as Dasatinib and Quercetin, can exert their effects by interfering with multiple pro - survival signaling networks, such as the Ephrin - Eph receptor signaling pathway, the PI3K - AKT pathway and BCL - 2 family proteins. In summary, this study aims to identify new selective clearance agents with multi - target mechanisms through computational and rational drug design methods, in the hope of more effectively combating aging - related diseases.